Media stories about Transgenomic (NASDAQ:PRPO) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Transgenomic earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 44.8044053658833 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Shares of Transgenomic (NASDAQ PRPO) traded up 7.78% during trading on Friday, hitting $1.94. The stock had a trading volume of 43,632 shares. The stock’s market capitalization is $15.75 million. The stock’s 50 day moving average is $2.75 and its 200 day moving average is $4.43. Transgenomic has a 52 week low of $1.51 and a 52 week high of $20.00.

Separately, ValuEngine cut Transgenomic from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 1st.

TRADEMARK VIOLATION WARNING: “Transgenomic (PRPO) Earning Somewhat Positive News Coverage, Study Shows” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at

Transgenomic Company Profile

Precipio, Inc, formerly Transgenomic, Inc, is a biotechnology company. The Company is engaged in advancing personalized medicine for the detection and treatment of cancer, and inherited diseases through its molecular technologies and clinical and research services. The Company operates through its Laboratory Services segment.

Insider Buying and Selling by Quarter for Transgenomic (NASDAQ:PRPO)

Receive News & Ratings for Transgenomic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transgenomic Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.